Bladder cancer in the elderly

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 6, 2009, Pages 653-667

  Shariat, Shahrokh F ^a   Milowsky, Matthew ^a   Droller, Michael J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b The Mount Sinai Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CARBOPLATIN; CISPLATIN; GEMCITABINE;

AGING; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CYSTECTOMY; EPIGENETICS; GENETIC ASSOCIATION; GERIATRIC CARE; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; URINARY DIVERSION; UROGENITAL TRACT CANCER;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; BCG VACCINE; CYSTECTOMY; EPIGENESIS, GENETIC; HUMANS; LIFE EXPECTANCY; RISK ASSESSMENT; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; URINARY DIVERSION;

EID: 70350474781     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.07.020     Document Type: Review

References (171)

1. Centers for Disease Control and Prevention (2008). www.cdc.gov/aging Accessed on December 16
2. Kent M.M., and Mather M. What drives U.S. population growth?. Population Bull 57 (2002) 1-40
3. Kinsella K., and Velkoff V.A. An aging world: 2005 U.S. census bureau, series P95/005-1 (2005), U.S. Government Printing Office, Wahsington, DC
4. www.census.gov UBoCw. Accessed November 10, 2008
5. Yancik R., and Ries L.A. Cancer in older persons: An international issue in an aging world. Semin Oncol 31 (2004) 128-136
6. Yancik R., and Ries L.A. Cancer in older persons. Magnitude of the problem-how do we apply what we know?. Cancer 74 (1994) 1995-2003
7. Yancik R., and Ries L.A. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14 (2000) 17-23
8. Edwards B.K., Howe H.L., Ries L.A., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94 (2002) 2766-2792
9. Hewitt M., Rowland J.H., and Yancik R. Cancer survivors in the United States: Age, health, and disability. J Gerontol A Biol Sci Med Sci 58 (2003) 82-91
10. Edwards B.K., Eisner M.P., and Kosary C.L. SEER cancer statistics review, 1975-2002 (2005), National Cancer Insitute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2002/ http://seer.cancer.gov/csr/1975_2002/
11. Boss G.R., and Seegmiller J.E. Age-related physiologic changes and their clinical significance. West J Med 135 (1981) 434-440
12. Campisi J. Aging and cancer cell biology, 2008. Aging Cell 7 (2008) 281-284
13. Shariat S.F., Karam J.A., and Lerner S.P. Molecular markers in bladder cancer. Curr Opin Urol 18 (2008) 1-8
14. Ehdaie B., and Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: Turning pathways into clinical biomarkers of prognosis. Expert Rev Anticancer Ther 8 (2008) 1103-1110
15. Wu X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
16. Miller C.A. Medicate with caution to prevent problems in frail elders. Geriatr Nurs 21 (2000) 108-109
17. Hurria A., Muss H.B., and Cohen H.J. Cancer and Aging (Chapter 75). In: Kufe D.W., et al. (Ed). Cancer Medicine (2003), B.C. Decker, Hamilton [chapter 75]
18. Edwards B.K., Brown M.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97 (2005) 1407-1427
19. Sawhney R., Sehl M., and Naeim A. Physiologic aspects of aging: Impact on cancer management and decision making, part I. Cancer J 11 (2005) 449-460
20. Sehl M., Sawhney R., and Naeim A. Physiologic aspects of aging: Impact on cancer management and decision making, part II. Cancer J 11 (2005) 461-473
21. Reuben D.B., Rubenstein L.V., Hirsch S.H., et al. Value of functional status as a predictor of mortality: Results of a prospective study. Am J Med 93 (1992) 663-669
22. Statistics. NCfH: Monitoring the Nation's Health. Trends in Health and Aging. http://www.cdc.gov/nchs/agingact.thm Accessed December 14, 2008
23. Dewys W.D., Begg C., Lavin P.T., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69 (1980) 491-497
24. Newman A.B., Yanez D., Harris T., et al. Weight change in old age and its association with mortality. J Am Geriatr Soc 49 (2001) 1309-1318
25. Pedelty L., and Gorelick P.B. Management of hypertension and cerebrovascular disease in the elderly. Am J Med 121 (2008) S23-S31
26. Baruch L. Hypertension and the elderly: More than just blood pressure control. J Clin Hypertens (Greenwich) 6 (2004) 249-255
27. Sharma G., and Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging 1 (2006) 253-260
28. Bhagra S., Nippoldt T.B., and Nair K.S. Dehydroepiandrosterone in adrenal insufficiency and ageing. Curr Opin Endocrinol Diabetes Obes 15 (2008) 239-243
29. Raynor M.C., Carson C.C., Pearson M.D., et al. Androgen deficiency in the aging male: A guide to diagnosis and testosterone replacement therapy. Can J Urol 1 Suppl 14 (2007) 63-68
30. Nass R., Johansson G., Christiansen J.S., et al. The aging population: Is there a role for endocrine interventions?. Growth Horm IGF Res 19 (2009) 89-100
31. Pardon M.C., and Rattray I. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders?. Neurosci Biobehav Rev 32 (2008) 1103-1120
32. Cherubini A., Lowenthal D.T., Paran E., et al. Hypertension and cognitive function in the elderly. Am J Ther 14 (2007) 533-554
33. Ferrucci L., Guralnik J.M., Salive M.E., et al. Cognitive impairment and risk of stroke in the older population. J Am Geriatr Soc 44 (1996) 237-241
34. Extermann M., and Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25 (2007) 1824-1831
35. Fulop T., Larbi A., Hirokawa K., et al. Immunosupportive therapies in aging. Clin Interv Aging 2 (2007) 33-54
36. Wu D., and Meydani S.N. Age-associated changes in immune and inflammatory responses: Impact of vitamin E intervention. J Leukoc Biol 84 (2008) 900-914
37. Kumar R., and Burns E.A. Age-related decline in immunity: Implications for vaccine responsiveness. Expert Rev Vaccines 7 (2008) 467-479
38. Weinberger B., Herndler-Brandstetter D., Schwanninger A., et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 46 (2008) 1078-1084
39. Schmucker D.L. Age-related changes in liver structure and function: Implications for disease?. Exp Gerontol 40 (2005) 650-659
40. Zeeh J., and Platt D. The aging liver: Structural and functional changes and their consequences for drug treatment in old age. Gerontology 48 (2002) 121-127
41. Muhlberg W., and Platt D. Age-dependent changes of the kidneys: Pharmacological implications. Gerontology 45 (1999) 243-253
42. Turnheim K. When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 38 (2003) 843-853
43. Fehrman-Ekholm I., and Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 38 (2004) 73-77
44. Want J., Kamas G., and Nguyen T.N. Disease management in the frail and elderly population: Integration of physicians in the intervention. Dis Manage 11 (2008) 23-28
45. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 14 (2007) 7-12
46. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 (2001) M146-M156
47. Walston J., and Fried L.P. Frailty and the older man. Med Clin North Am 83 (1999) 1173-1194
48. Yancik R., Havlik R.J., Wesley M.N., et al. Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 6 (1996) 399-412
49. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35 (2000) 181-200
50. Satariano W.A., and Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120 (1994) 104-110
51. Welch H.G., Albertsen P.C., Nease R.F., et al. Estimating treatment benefits for the elderly: The effect of competing risks. Ann Intern Med 124 (1996) 577-584
52. Cusack B.J. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2 (2004) 274-302
53. Brandtstadter J., and Renner G. Tenacious goal pursuit and flexible goal adjustment: Explication and age-related analysis of assimilative and accommodative strategies of coping. Psychol Aging 5 (1990) 58-67
54. Lockenhoff C.E., and Carstensen L.L. Socioemotional selectivity theory, aging, and health: The increasingly delicate balance between regulating emotions and making tough choices. J Pers 72 (2004) 1395-1424
55. Sanderman R., Coyne J.C., and Ranchor A.V. Age: Nuisance variable to be eliminated with statistical control or important concern?. Patient Educ Couns 61 (2006) 315-316
56. Hurria A., Lachs M.S., Cohen H.J., et al. Geriatric assessment for oncologists: Rationale and future directions. Crit Rev Oncol Hematol 59 (2006) 211-217
57. DePinho R.A. The age of cancer. Nature 408 (2000) 248-254
58. Irminger-Finger I. Science of cancer and aging. J Clin Oncol 25 (2007) 1844-1851
59. Schumacher B., Garinis G.A., and Hoeijmakers J.H. Age to survive: DNA damage and aging. Trends Genet 24 (2008) 77-85
60. Feng Z., Hu W., Rajagopal G., et al. The tumor suppressor p53: Cancer and aging. Cell Cycle 7 (2008) 842-847
61. Itahana K., Dimri G., and Campisi J. Regulation of cellular senescence by p53. Eur J Biochem 268 (2001) 2784-2791
62. Campisi J. Analysis of tumor suppressor gene-induced senescence. Methods Mol Biol 223 (2003) 155-172
63. Kirkwood T.B. p53 and aging: Too much of a good thing?. Bioessays 24 (2002) 577-579
64. Shariat S.F., Ashfaq R., Sagalowsky A.I., et al. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol (2006)
65. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
66. Langen R.C., Korn S.H., and Wouters E.F. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 35 (2003) 226-235
67. Allsopp R.C., Chang E., Kashefi-Aazam M., et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res 220 (1995) 194-200
68. Metcalfe J.A., Parkhill J., Campbell L., et al. Accelerated telomere shortening in ataxia telangiectasia. Nat Genet 13 (1996) 350-353
69. Deng Y., Chan S.S., and Chang S. Telomere dysfunction and tumor suppression: The senescence connection. Nat Rev Cancer 8 (2008) 450-458
70. Artandi S.E., Alson S., Tietze M.K., et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci USA 99 (2002) 8191-8196
71. Artandi S.E., and DePinho R.A. Mice without telomerase: What can they teach us about human cancer?. Nat Med 6 (2000) 852-855
72. de Lange T., and DePinho R.A. Unlimited mileage from telomerase?. Science 283 (1999) 947-949
73. Cunningham A.P., Love W.K., Zhang R.W., et al. Telomerase inhibition in cancer therapeutics: Molecular-based approaches. Curr Med Chem 13 (2006) 2875-2888
74. Campisi J., Kim S.H., Lim C.S., et al. Cellular senescence, cancer, and aging: The telomere connection. Exp Gerontol 36 (2001) 1619-1637
75. Opitz O.G. Telomeres, telomerase, and malignant transformation. Curr Mol Med 5 (2005) 219-226
76. Ito H., Kyo S., Kanaya T., et al. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 4 (1998) 1603-1608
77. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
78. Wu X., Amos C.I., Zhu Y., et al. Telomere dysfunction: A potential cancer predisposition factor. J Natl Cancer Inst 95 (2003) 1211-1218
79. Herman M.P., Svatek R.S., Lotan Y., et al. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol Nefrol 60 (2008) 217-235
80. Messing E.M. Urothelial tumors of the bladder (Chapter 75). In: Campbell-Walsh (Ed). Urology. 9th ed. (2008), Saunders Elsevier 2407-2446 [chapter 75]
81. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
82. Shi B., Zhang K., Zhang J., et al. Relationship between patient age and superficial transitional cell carcinoma characteristics. Urology 71 (2008) 1186-1190
83. McGrath M., Michaud D.S., and De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 163 (2006) 236-244
84. Schultzel M., Saltzstein S.L., Downs T.M., et al. Late age (85 years or older) peak incidence of bladder cancer. J Urol 179 (2008) 1302-1305 Discussion 1305-6
85. Momose H., Kakinuma H., Shariff S.Y., et al. Tumor-promoting effect of urinary epidermal growth factor in rat urinary bladder carcinogenesis. Cancer Res 51 (1991) 5487-5490
86. Benson Jr. R.C., Tomera K.M., and Kelalis P.P. Transitional cell carcinoma of the bladder in children and adolescents. J Urol 130 (1983) 54-55
87. Fitzpatrick J.M., and Reda M. Bladder carcinoma in patients 40 years old or less. J Urol 135 (1986) 53-54
88. Linn J.F., Sesterhenn I., Mostofi F.K., et al. The molecular characteristics of bladder cancer in young patients. J Urol 159 (1998) 1493-1496
89. Madgar I., Goldwasser B., Nativ O., et al. Long-term follow-up of patients less than 30 years old with transitional cell carcinoma of bladder. J Urol 139 (1988) 933-934
90. Witjes J.A., and Debruyne F.M. Bladder carcinoma in patients less than 40 years of age. Urol Int 44 (1989) 81-83
91. Resorlu B., Beduk Y., Baltaci S., et al. The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy. BJU Int (2008)
92. Nielsen M.E., Shariat S.F., Karakiewicz P.I., et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51 (2007) 699-706 Discussion 706-8
93. Johnson D.E., and Hillis S. Carcinoma of the bladder in patients less than 40 years old. J Urol 120 (1978) 172-173
94. Kurz K.R., Pitts W.R., and Vaughan Jr. E.D. The natural history of patients less than 40 years old with bladder tumors. J Urol 137 (1987) 395-397
95. Kutarski P.W., and Padwell A. Transitional cell carcinoma of the bladder in young adults. Br J Urol 72 (1993) 749-755
96. Wan J., and Grossman H.B. Bladder carcinoma in patients age 40 years or younger. Cancer 64 (1989) 178-181
97. Yossepowitch O., and Dalbagni G. Transitional cell carcinoma of the bladder in young adults: Presentation, natural history, and outcome. J Urol 168 (2002) 61-66
98. Solana R., Pawelec G., and Tarazona R. Aging and innate immunity. Immunity 24 (2006) 491-494
99. Herr H.W. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology 70 (2007) 65-68
100. Joudi F.N., Smith B.J., O'Donnell M.A., et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 (2006) 1634-1639 Discussion 1639-40
101. Palou J., Angerri O., Segarra J., et al. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 76 (2003) 1514-1516
102. Yossepowitch O., Eggener S.E., Bochner B.H., et al. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol 176 (2006) 482-485
103. Malkowicz S.B. Management of superficial bladder cancer. Campbell's Urology. 8th ed. (2002), Saunders Elsevier, Philadelphia (PA) 2789-2792 2002
104. Gonzalez J.A., Marcol B.R., and Wolf M.C. Complications of intravesical bacillus Calmette-Guerin: A case report. J Urol 148 (1992) 1892-1893
105. Leebeek F.W., Ouwendijk R.J., Kolk A.H., et al. Granulomatous hepatitis caused by bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation. Gut 38 (1996) 616-618
106. Marans H.Y., and Bekirov H.M. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy for bladder carcinoma. J Urol 137 (1987) 111-112
107. Orikasa K., Namima T., Ota S., et al. Acute eosinophilic pneumonia associated with intravesical bacillus Calmette-Guerin therapy of carcinoma in situ of the bladder. Int J Urol 10 (2003) 622-624
108. Rawls W.H., Lamm D.L., Lowe B.A., et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 144 (1990) 1328-1330
109. Heiner J.G., and Terris M.K. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol Oncol 26 (2008) 137-140
110. Hudson M.A., Brown E.J., Ritchey J.K., et al. Modulation of fibronectin-mediated bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51 (1991) 3726-3732
111. Hudson M.A., Yuan J.J., Catalona W.J., et al. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 144 (1990) 1362-1364
112. P'Ng K.B., Walsh M.D., Seymour G.J., et al. The adverse effect of fibrin-clot inhibiting drugs on intravesical bacillus Calmette-Guerin efficacy for superficial bladder cancer. Aust N Z J Surg 63 (1993) 127-130
113. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
114. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the bladder cancer research consortium. J Urol 176 (2006) 2414-2422
115. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003) 859-866
116. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
117. Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 48 (2005) 189-199 Discussion 199-201
118. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48 (2005) 202-205 Discussion 205-6
119. Pectasides D., Pectasides M., and Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: Literature review. Eur Urol 48 (2005) 60-67 Discussion 67-8
120. Schultz P.K., Herr H.W., Zhang Z.F., et al. Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 12 (1994) 1394-1401
121. Sonpavde G., and Petrylak D.P. Perioperative chemotherapy for bladder cancer. Crit Rev Oncol Hematol 57 (2006) 133-144
122. Prout Jr. G.R., Wesley M.N., Yancik R., et al. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: A population-based study. Cancer 104 (2005) 1638-1647
123. Hollenbeck B.K., Miller D.C., Taub D., et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology 64 (2004) 292-297
124. Muss H.B., Biganzoli L., Sargent D.J., et al. Adjuvant therapy in the elderly: Making the right decision. J Clin Oncol 25 (2007) 1870-1875
125. Clark P.E., Stein J.P., Groshen S.G., et al. Radical cystectomy in the elderly: Comparison of clinical outcomes between younger and older patients. Cancer 104 (2005) 36-43
126. Nielsen M.E., Shariat S.F., Karakiewics P.I., et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51 (2007) 699-706 Discussion 706-8
127. Thrasher J.B., Frazier H.A., Robertson J.E., et al. Clinical variables, which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 73 (1994) 1708-1715
128. Nielsen M.E., Palapattu G.S., Karakiewicz P.I., et al. A delay in radical cystectomy of more than 3 months is not associated with a worse clinical outcome. BJU Int 100 (2007) 1015-1020
129. Chang S.S., Hassan J.M., Cookson M.S., et al. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathologic stage. J Urol 170 (2003) 1085-1087
130. Sanchez-Ortiz R.F., Huang W.C., Mick R., et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169 (2003) 110-115 Discussion 115
131. Miller D.C., Taub D.A., Dunn R.L., et al. The impact of comorbid disease on cancer control and survival following radical cystectomy. J Urol 169 (2003) 105-109
132. Kopie T.M., Serio A.M., Vickers A.J., et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 112 (2008) 2384-2392
133. Weizer A.Z., Joshi D., Daignault S., et al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 177 (2007) 1287-1293
134. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 21 (2003) 690-696
135. Shabsigh A., Korets R., Vora K.C., et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol (2008)
136. Donat S.M., Shabsigh A., Savage C., et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: A high-volume tertiary cancer center experience. Eur Urol (2008) [Epub ahead of print]
137. Rosario D.J., Becker M., and Anderson J.B. The changing pattern of mortality and morbidity from radical cystectomy. BJU Int 85 (2000) 427-430
138. Parekh D.J., Gilbert W.B., Koch M.O., et al. Continent urinary reconstruction vs. ileal conduit: A contemporary single-institution comparison of perioperative morbidity and mortality. Urology 55 (2000) 852-855
139. Farnham S.B., Cookson M.S., Alberts G., et al. Benefit of radical cystectomy in the elderly patient with significant comorbidities. Urol Oncol 22 (2004) 178-181
140. Figueroa A.J., Stein J.P., Dickinson M., et al. Radical cystectomy for elderly patients with bladder carcinoma: An updated experience with 404 patients. Cancer 83 (1998) 141-147
141. Parekh D.J., Clark T., O'Connor J., et al. Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and comorbid medical conditions. J Urol 168 (2002) 2454-2456
142. Fairey A., Chetner M., Metcalfe J., et al. Associations among age, comorbidity, and clinical outcomes after radical cystectomy: Results from the Alberta Urology Institute radical cystectomy database. J Urol 180 (2008) 128-134 Discussion 134
143. Konety B.R., Dhawan V., Allareddy V., et al. Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: Data from the health care utilization project. J Urol 173 (2005) 1695-1700
144. Hollenbeck B.K., Miller D.C., Taub D., et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol 174 (2005) 1231-1237 Discussion 1237
145. Siegrist T.C., Savage C.J., Cronin A.M., et al. Radical cystectomy (RC) in octogenarians: Does morbidity outweigh the potential survival benefits?. J Urol 181 (2009) 633
146. Herr H.W. Transurethral resection of muscle-invasive bladder cancer: Ten-year outcome. J Clin Oncol 19 (2001) 89-93
147. Kassouf W., Swanson D., Kamat A.M., et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: A contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175 (2006) 2058-2062
148. Holzbeierlein J.M., Lopez-Corona E., Bochner B.H., et al. Partial cystectomy: A contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 172 (2004) 878-881
149. Shelley M., Barber J., Wilt T., et al. Surgery vs. radiotherapy for muscle invasive bladder cancer?. Clin Oncol (R Coll Radiol) 15 (2003) 167-168
150. Shipley W.U., Zietman A.L., Kaufman D.S., et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 15 (2005) 36-41
151. Zietman A.L., Sacco D., Skowronski U., et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy, and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 170 (2003) 1772-1776
152. Kachnic L.A., Kaufman D.S., Heney N.M., et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15 (1997) 1022-1029
153. Montie J.E. Against bladder sparing Surgery. J Urol 162 (1999) 452-455 Discussion 455-7
154. Stroumbakis N., Herr H.W., Cookson M.S., et al. Radical cystectomy in the octogenarian. J Urol 158 (1997) 2113-2117
155. Sogni F., Brausi M., Frea B., et al. Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology 71 (2008) 919-923
156. Madersbacher S., Mohrle K., Burkhard F., et al. Long-term voiding pattern of patients with ileal orthotopic bladder substitutes. J Urol 167 (2002) 2052-2057
157. Hautmann R.E., Miller K., Steiner U., et al. The ileal neobladder: Six years of experience with more than 200 patients. J Urol 150 (1993) 40-45
158. Hugonnet C.L., Danuser H., Springer J.P., et al. Decreased sensitivity in the membranous urethra after orthotopic ileal bladder substitute. J Urol 161 (1999) 418-421
159. Kessler T.M., Burkhard F.C., Perimenis P., et al. Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J Urol 172 (2004) 1323-1327
160. Cohen H.J. The cancer aging interface: A research agenda. J Clin Oncol 25 (2007) 1945-1948
161. Lichtman S.M., Wildiers H., Chatelut E., et al. International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 25 (2007) 1832-1843
162. Surbone A., Kagawa-Singer M., Terret C., et al. The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol 18 (2007) 633-638
163. Terret C., Zulian G., and Droz J.P. Statements on the interdependence between the oncologist and the geriatrician in geriatric oncology. Crit Rev Oncol Hematol 52 (2004) 127-133
164. Terret C., Zulian G.B., Naiem A., et al. Multidisciplinary approach to the geriatric oncology patient. J Clin Oncol 25 (2007) 1876-1881
165. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 (2005) 241-252
166. Li S.H., Chen W.H., Tang Y., et al. Incidence of ischemic stroke post-chemotherapy: A retrospective review of 10,963 patients. Clin Neurol Neurosurg 108 (2006) 150-156
167. Dash A., Galsky M.D., Vickers A.J., et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107 (2006) 506-513
168. Castagneto B., Zai S., Marenco D., et al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: Response to treatment and correlation with the comprehensive geriatric assessment. Oncology 67 (2004) 27-32
169. Bamias A., Lainakis G., Kastritis E., et al. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: Report of efficacy, quality of life, and geriatric assessment. Oncology 73 (2007) 290-297
170. Morrison V.A., Picozzi V., Scott S., et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: A risk factor analysis. Clin Lymphoma 2 (2001) 47-56
171. Kemeny M.M. Surgery in older patients. Semin Oncol 31 (2004) 175-184